Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling
The Federal Circuit on Friday said it wouldn't reconsider the invalidation of four patents covering Acorda Therapeutics Inc.'s flagship multiple sclerosis drug Ampyra, despite the drugmaker's argument that the decision had...To view the full article, register now.
Already a subscriber? Click here to view full article